Key points are not available for this paper at this time.
Increasing experience in the use of PLLA-SCA™ suggests that a brief overview of recent studies and a standardization of treatment protocols based on new clinical data should be beneficial. The aim of this article is to provide guidance on the use of PLLA-SCA™ based on data from the literature and the experience of five plastic surgeons and one aesthetic physician, with a focus on Italian patients. To this effect, the authors convened online to discuss various aspects related to PLLA-SCA™ treatment of both the face and non-facial body areas. For each topic, the authors developed recommendations, addressing patient selection, product preparation and injection protocols. Suggestions regarding the combination of PLLA-SCA™ with other aesthetic treatments and the prevention of adverse events were also included. The authors suggest using dilution volumes of 8 mL of sterile water for injection (SWFI) plus 1 mL lidocaine for the face and 17 mL SWFI plus 1 mL lidocaine for body areas and immediate use after product reconstitution. By adhering to the latest instructions about product reconstitution, the occurrence of complications is minimized. In the Authors’ experience, PLLA-SCA™ can be used safely and effectively for cosmetic enhancement of multiple body areas.
Innocenti et al. (Tue,) studied this question.